eISSN: 2345-2781
Editorial Board
Aims and Scope
Current Issue
All Issues
Publisher
Search
Sitemap
Rss
Contact Us
Indexes

















Journal of Renal Injury Prevention 2017;6(3):177-183. doi:10.15171/jrip.2017.34
Cell cycle arrest biomarkers for the early prediction of acute kidney injury - full of promise, but not a must–have for yet

Review Article

Helmut Schiffl *

1 Department of Internal Medicine IV, University Hospital Munich, Munich, Germany


*Corresponding author: Prof. Dr. Helmut Schiffl,
Email: h-schiffl@t-online.de

Abstract
Hospital acquired acute kidney injury (AKI) is one of the most common organ dysfunctions in elderly and critically ill patients and adversely impacts on short-term as well as on long-term clinical outcomes. Early diagnosis of AKI, preferably within 12 to 24 hours after onset of the renal insult, is pivotal to the development of effective therapies attenuating acute kidney dysfunction severity or fastening renal recovery. Traditional biomarkers like creatinine are late indicators of AKI. The cell cycle arrest biomarkers (CCABs) tissue inhibitor of metalloproteinase-2 and insulin like growth factor binding protein-7 accurately predicted moderate to severe AKI in high-risk cardiothoracic surgery patients within 12 hours. These CCABs outperformed the most promising current biomarkers. The NephroCheck test system represents a promising tool inching closer to widespread clinical application and received FDA approval in September 2014. However, there is an urgent need to demonstrate the cost-effectiveness of this biomarker test system whether alone or in combination with biomarkers of other pathways. Most importantly, further trials should validate the cut-off values in patient populations other than intensive care unit (ICU) and cardiac surgery.

Notes

Implication for health policy/practice/research/medical education:

The cell cycle arrest biomarkers (CCABs) tissue inhibitor of metalloproteinase- 2 and insulin like growth factor binding protein -7 accurately predicted moderate to severe acute kidney injury (AKI) in high-risk cardiothoracic surgery patients within 12 hours. These CCABs outperformed the most promising current biomarkers. The NephroCheck test system represents a promising tool inching closer to widespread clinical application and received FDA approval in September 2014. However, there is an urgent need to demonstrate the cost-effectiveness of this biomarker test system whether alone or in combination with biomarkers of other pathways. Most importantly, further trials should validate the cut-off values in patient populations other than intensive care unit (ICU) and cardiac surgery.

Please cite this paper as: Schiffl H. Cell cycle arrest biomarkers for the early prediction of acute kidney injury - full of promise, but not a must–have for yet. J Renal Inj Prev. 2017;6(3):177-183. DOI: 10.15171/jrip.2017.34.


Comments
First name  
Last name  
Email address  
Comments  
Security code



Article
PDF


Export citation
EndNote
Reference Manager
BibTeX
Medlars
Refworks

Cite by
Google Scholar
PubMed

Google Scholar
Articles by Helmut Schiffl
Similar articles
Related articles

PubMed
Articles by Helmut Schiffl


Article Access Statistics
Viewed
PDF Downloaded
Comments

Share this article!
Creative Commons Attribution 4.0 License This work is licensed under a Creative Commons Attribution 4.0 License.
Copyright © 2016 The Author(s)
Published by Nickan Research Institute